Adjuvant Atezolizumab for Early Triple-Negative Breast Cancer

JAMA, Journal Year: 2025, Volume and Issue: unknown

Published: Jan. 30, 2025

Importance Triple-negative breast cancer is an aggressive subtype with a high incidence in young patients, non-Hispanic Black women, and risk of progression to metastatic cancer, devastating sequela 12- 18-month life expectancy. Until recently, one strategy for treating early-stage triple-negative was chemotherapy after surgery. However, it not known whether the addition immune therapy postsurgery would be beneficial. Objective To evaluate form atezolizumab postoperative patients high-risk subtype. Design, Setting, Participants In this open-label international randomized phase 3 trial conducted more than 330 centers 31 countries, undergoing surgery as initial treatment stage II or III were enrolled between August 2, 2018, November 11, 2022. The last patient follow-up on 18, 2023. Interventions Patients (1:1) receive standard 20 weeks (n = 1101) without 1098) drug up 1 year. Main Outcomes Measures primary end point invasive disease-free survival (time randomization same opposite breast, recurrence elsewhere body, death from any cause). Results median age 53 years most self-reported being Asian White race neither Latino nor Hispanic ethnicity. study independent data monitoring committee halted enrollment at 2199 2300 planned patients. All stopped following early interim futility analysis. continued premature final With events 141 (12.8%) treated atezolizumab-chemotherapy 125 (11.4%) alone (median follow-up, 32 months), stratified hazard ratio 1.11 (95% CI, 0.87-1.42; P .38). Compared alone, regimen plus associated treatment-related grade 4 adverse (54% vs 44%) but similar incidences fatal (0.8% 0.6%) leading discontinuation. Chemotherapy exposure 2 groups. Conclusions Relevance did provide benefit among who are recurrent disease. Trial Registration ClinicalTrials.gov Identifier: NCT03498716

Language: Английский

---

Predicting Axillary Lymph Node Metastasis in Young Onset Breast Cancer: A Clinical-Radiomics Nomogram Based on DCE-MRI

Breast Cancer Targets and Therapy, Journal Year: 2025, Volume and Issue: Volume 17, P. 103 - 113

Published: Jan. 1, 2025

Young onset breast cancer, diagnosed in women under 50, is known for its aggressive nature and challenging prognosis. Precisely forecasting axillary lymph node metastasis (ALNM) essential customizing treatment plans enhancing patient results. This research sought to create verify a clinical-radiomics nomogram that combines radiomic features from Dynamic Contrast-Enhanced Magnetic Resonance Imaging (DCE-MRI) with standard clinical predictors improve the accuracy of predicting ALNM young cancer patients. We performed retrospective analysis at one facility, involving creation validation two stages.At first, medical model was developed utilizing conventional indicators like tumor dimensions, molecular classifications, multifocal presence, MRI-determined ALN status.A more detailed subsequently by integrating characteristics derived DCE-MRI images.These models were created using logistic regression analyses on training dataset, their effectiveness assessed measuring area receiver operating characteristic curve (AUC) separate dataset. The surpassed clinical-only model, recording an AUC 0.892 dataset 0.877 dataset.Significant included MRI-reported status select features, which markedly enhanced model's predictive capacity. Integrating significantly improves prediction providing valuable tool personalized planning. study underscores potential merging advanced imaging data insights refine oncological models. Future should expand multicentric studies include genomic boost nomogram's generalizability precision.

Language: Английский

---

Quality of care in Colombian women with early-onset breast cancer in two time periods: findings from a nationwide administrative registry cohort

The Lancet Regional Health - Americas, Journal Year: 2025, Volume and Issue: 43, P. 101018 - 101018

Published: Feb. 13, 2025

Language: Английский

---

Labdane Diterpenoids from Leonotis ocymifolia with Selective Cytotoxic Activity Against HCC70 Breast Cancer Cell Line

Diseases, Journal Year: 2025, Volume and Issue: 13(5), P. 140 - 140

Published: May 1, 2025

Background: Triple-negative breast cancer (TNBC) is an aggressive subtype of with limited therapeutic options. Leonotis ocymifolia a shrub widely used in traditional medicine to alleviate cancer-related symptoms. In search find safe and efficacious agents from medicinal plants, was studied compounds anticancer activity against TNBC. Methods: Compounds were characterized using spectroscopic data such as IR, 1D 2D NMR, MS spectrometry evaluated for cytotoxic triple-negative (HCC70), hormone receptor-positive (MCF-7), non-tumorigenic mammary epithelial cell lines (MCF-12A). Results: A previously unreported bis-spirolabdane, 13S-nepetaefolin (1), together five known labdane diterpenoids, namely nepetaefolin (2), dubiin (3), nepetaefuran (4), leonotin (5), leonotinin (6), the genus isolated. Overall, diterpenoids showed selective toward cells (HCC70). Of extracted, demonstrated greatest IC50 24.65 µM (SI = 1.08) HCC70 cells; however, it equally MCF-12A (IC50 26.55 µM), whereas its isomer (2) no activity. This suggests that stereochemistry might have effect on bis-spirolabdane diterpenoids. All (1–6) adsorption, distribution, metabolism, excretion properties (ADME), while (5) (6) exhibited lead-like high synthetic accessibility scores. Conclusions: The findings this study warrant further investigation L. potential agents, including chemical derivatization bis-spiro diterpenoid (1) improve selectivity TNBC over non-cancer cells.

Language: Английский

---

SOX13-mediated transcription of LRP11 enhances malignant properties of tumor cells and CD8+ T cell inactivation in breast cancer through the β-catenin/PD-L1 axis

Cellular Signalling, Journal Year: 2024, Volume and Issue: 124, P. 111383 - 111383

Published: Sept. 6, 2024

Language: Английский

---

Molecular mechanism of oroxyli semen against triple-negative breast cancer verified by bioinformatics and in vitro experiments

Medicine, Journal Year: 2023, Volume and Issue: 102(37), P. e34835 - e34835

Published: Sept. 15, 2023

This study aimed to use network pharmacology predict the therapeutic mechanism of oroxyli semen (OS) on triple-negative breast cancer (TNBC) and validate it through in vitro experiments.The active ingredients target proteins OS were retrieved from Traditional Chinese Medicine Systems Pharmacology database, TNBC-related genes obtained GeneCards database. The overlapping used construct a protein-protein interaction (PPI) via String Furthermore, we employed an online bioinformatics analysis platform (https://www.bioinformatics.com.cn/) perform gene ontology Kyoto Encyclopedia Genes Genomes pathway enrichment analyses evaluate biological processes, molecular functions, cellular components generate simulated signal pathways. Additionally, docking was binding ability small molecule drugs signaling targets. CCK8 assay conducted detect effect TNBC cell viability, Western Blot utilized verify expression AKT, VEGF, hypoxia-inducible factor 1-alpha (HIF-1α) proteins.Fifteen 166 targets Venn diagram revealed that 163 related TNBC. identified AKT1, IL-6, JUN, vascular endothelial growth A (VEGFA), CASP3, HIF-1α as potential core which may treat results indicated ingredient chryseriol had good with VEGFA, HIF-1α. inhibited viability MDA-MB-231 BT-20 cells. demonstrated intervention led decrease protein compared control group (P < .05), increased cleaved PARP.OS exert its effects multiple Chryseriol, component OS, can enhance apoptosis cells by targeting VEGFA/HIF-1α pathway. provided new insights into for aid development novel approaches

Language: Английский

---

Breast Cancer, a Global Health Crisis

International journal of new findings in health and educational sciences (IJHES)., Journal Year: 2023, Volume and Issue: 1(2), P. 79 - 87

Published: June 28, 2023

Breast cancer is still a public health problem worldwide and currently the most common tumor in world. life-threatening disease women leading cause of death female population. heterogeneous disorder with different molecular subtypes biological characteristics, therapeutic functions clinical outcomes for each subtype. Furthermore, treatment BC complicated by intratumoral complexity. Consequently, breast risk assessment an important part health. Precision medicine practice diagnosis, treatment, screening prevention that takes into account patient's genetic makeup. Therefore, identifying who are at high cancer, it possible to make personalized recommendations regarding methods, age which should begin, frequency completing screenings, individual counselling.

Language: Английский

---

Knowledge and Practice of Breast Self-Examination (BSE) Among Urban Women of a Low-Resource Country

ANNALS OF ABBASI SHAHEED HOSPITAL AND KARACHI MEDICAL & DENTAL COLLEGE, Journal Year: 2023, Volume and Issue: 28(2), P. 96 - 103

Published: May 30, 2023

Objective: To assess the knowledge, attitude & practices of breast self-examination among women residing in district 'Central' Karachi and to determine high risk Ca central Karachi. Methods: This descriptive, cross-sectional, questionnaire-based, study was carried out attending a charitable hospital Karachi, 2018. The data collected through convenience sampling technique, analyzed by using SPSS version 24.0. Descriptive statistics socio-demographic variables were presented as mean ± SD for continuous frequency or percentages categorical variables. Chi-square test used association between practice regarding self-examination, p-value <0.05 consider significant, Results: age 172 participants 30.73±6.84 years, 34.9% educated with primary education, 41.9% had 5-7 family members. 90.1% married 92.4% housewives. All Muslims. 65.7% females heard BSE source information their However, 50.6 % practicing BSE, while 24.1% execute it monthly, 75.9% preferred examine breasts fingers opposite hand, 77.3% agreed important health. There an 63.3% highest aged 31-40 years lowest 42.7% those 20-30 (p=0.041). About 75% who graduated, performed compared only 40% uneducated (p=0.270) Conclusion: low there is dire need implementation health education programme on early detection breast. required beast.

Language: Английский

---

Addressing the Rising Trend in Early-Age-Onset Cancers in Canada

Current Oncology, Journal Year: 2024, Volume and Issue: 31(7), P. 4063 - 4078

Published: July 19, 2024

A multi-disciplinary symposium on early-age onset cancer (EAOC) was held in October 2023 to explore challenges experienced by this rapidly growing population. major outcome of the recognition remarkable similarities EAOC patients’ journeys across sites. Prevention and early detection are hindered a lack awareness among patients family doctors that can does occur younger persons. Distinct characteristics disease—such as later stage at diagnosis more aggressive tumor biology—require potent treatments, which result profound physical psychosocial consequences unique age group. patient empowerment emerged another key theme symposium. The development greater number specialized clinics called for, support groups were recognized for vital role they play empowering their families. Leading-edge medical advancements hold tremendous hope spectrum care. New technologies based genomic profiling, immunotherapy microbiome alteration contribute highly effective, personalized approaches treatment. All participants expressed commitment speak with one resounding voice advocate equitable access leading care practices patients; thus, fourth is planned November 2024.

Language: Английский

---

Mass Spectrometry-Based Proteomics for Classification and Treatment Optimisation of Triple Negative Breast Cancer

Journal of Personalized Medicine, Journal Year: 2024, Volume and Issue: 14(9), P. 944 - 944

Published: Sept. 5, 2024

Triple-negative breast cancer (TNBC) presents a significant medical challenge due to its highly invasive nature, high rate of metastasis, and lack drug-targetable receptors, which together lead poor prognosis limited treatment options. The traditional guidelines for early TNBC are based on multimodal approach integrating chemotherapy, surgery, radiation associated with low overall survival relapse rates. Therefore, the treating has shifted towards neoadjuvant (NAC), given patient before surgery aims reduce tumour size, risk recurrence, improve pathological complete response (pCR) rate. However, recent studies have shown that NAC is only 30% patients achieving pCR. Thus, novel predictive biomarkers essential if decisions be optimised chemotherapy toxicities minimised. Given heterogeneity TNBC, mass spectrometry-based proteomics technologies offer valuable tools discovery targetable prediction toxicity. These can serve as critical targets therapeutic intervention. This review provide comprehensive overview diagnosis treatment, highlighting need new approach. Specifically, it highlights how address key unmet clinical needs by identifying protein distinguish prognostication between groups who being treated NAC. By proteomic insights, we anticipate enhanced personalisation, improved outcomes, ultimately, increased rates patients.

Language: Английский

---